Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
254.47B | 244.38B | 195.19B | 180.03B | 174.27B | 160.55B | Gross Profit |
254.47B | 244.38B | 195.19B | 180.03B | 174.27B | 160.55B | EBIT |
6.84B | 5.27B | 5.51B | 8.40B | 6.79B | 10.87B | EBITDA |
11.02B | 9.48B | 9.99B | 12.56B | 10.92B | 15.11B | Net Income Common Stockholders |
5.03B | 3.43B | 5.16B | 6.70B | 5.37B | 8.46B |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
5.56B | 7.55B | 8.75B | 6.83B | 6.00B | 11.51B | Total Assets |
155.77B | 155.88B | 152.76B | 143.93B | 154.89B | 155.45B | Total Debt |
37.41B | 31.97B | 30.93B | 31.09B | 33.67B | 32.92B | Net Debt |
32.79B | 24.42B | 23.11B | 25.17B | 28.59B | 22.74B | Total Liabilities |
110.39B | 114.64B | 106.41B | 98.98B | 107.70B | 105.06B | Stockholders Equity |
45.34B | 41.03B | 46.22B | 44.87B | 47.11B | 50.32B |
Cash Flow | Free Cash Flow | ||||
6.01B | 8.96B | 10.24B | 7.36B | 6.04B | 9.26B | Operating Cash Flow |
7.44B | 10.36B | 11.81B | 8.66B | 7.19B | 10.35B | Investing Cash Flow |
-410.00M | -2.10B | -5.17B | 3.10B | -3.61B | 2.98B | Financing Cash Flow |
-8.80B | -7.65B | -4.29B | -11.24B | -8.21B | -8.53B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $27.45B | 8.30 | 12.59% | ― | 8.85% | 33.30% | |
72 Outperform | $27.84B | 16.31 | 10.09% | 1.53% | 10.09% | -12.18% | |
71 Outperform | $88.87B | 15.35 | 14.24% | 1.68% | 6.63% | -3.26% | |
71 Outperform | $83.40B | 17.30 | 12.37% | 1.83% | 24.65% | 48.38% | |
69 Neutral | $275.06B | 12.68 | 24.33% | 2.77% | 8.68% | 45.24% | |
69 Neutral | $80.43B | 15.19 | 7.00% | 4.18% | 4.84% | -26.54% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% |
On June 2, 2025, The Cigna Group announced the appointment of Michael J. Hennigan to its Board of Directors. Hennigan, who has a robust background in the energy sector, is expected to bring valuable strategic insights and leadership to Cigna, aiding in its mission to improve healthcare experiences and drive growth.
The most recent analyst rating on (CI) stock is a Buy with a $376.00 price target. To see the full list of analyst forecasts on Cigna stock, see the CI Stock Forecast page.
The Cigna Group has announced its intention to reaffirm its projected consolidated adjusted income from operations for the full year 2025, expecting at least $29.60 per share. This announcement, made during meetings with investors and analysts, highlights the company’s confidence in its financial performance and strategic direction despite the inherent uncertainties and risks in the healthcare sector.
The most recent analyst rating on (CI) stock is a Buy with a $376.00 price target. To see the full list of analyst forecasts on Cigna stock, see the CI Stock Forecast page.
On April 24, 2025, The Cigna Group entered into a new $6.5 billion Revolving Credit and Letter of Credit Agreement with several banks, replacing its existing credit facilities. This agreement, which can be increased to $8 billion, is intended for general corporate purposes and includes various interest rate options and covenants, such as maintaining a leverage ratio not exceeding 0.60 to 1.00. Additionally, on April 22, 2025, Noelle Eder, the Executive Vice President and Global Chief Information Officer, resigned, effective May 16, 2025, for personal reasons. The company’s Annual Meeting of Shareholders on April 23, 2025, saw the election of eleven directors and the approval of executive compensation, among other proposals.
On March 13, 2025, Cigna announced the termination of Eric P. Palmer, Executive Vice President for Enterprise Strategy and CEO of Evernorth Health Services, effective April 26, 2025. The agreement includes a severance package with cash payments and continued vesting of certain equity awards, reflecting the company’s strategic management decisions and impacting its leadership structure.
On March 13, 2025, Cigna announced leadership changes effective March 31, 2025, with Brian C. Evanko becoming President and COO, and Ann M. Dennison stepping in as CFO. These changes come with new compensation arrangements reflecting their roles. Additionally, the company reaffirmed its projected 2025 financial outlook, including consolidated adjusted income from operations of at least $29.50 per share and significant pre-tax income from its Evernorth and Cigna Healthcare segments.